ADCs combine antibodies with drug payloads for targeted therapy, but complex manufacturing requires monitoring CQAs across multiple entities.
Early-phase oncology trials carry substantial scientific and commercial risk in cancer drug development. Getting them right ...
Q4 2025 Earnings Call February 10, 2026 4:30 PM ESTCompany ParticipantsJacquie Ross - Senior Vice President of Treasury ...
Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.
The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Henry Boot PLC - Sheffield, England-based construction and property ...
Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.
Evogene Ltd. , a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, Systasy Bioscience GmbH, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results